Skip to main content
. 2022 Feb 15;10(2):E200–E208. doi: 10.1055/a-1675-2334

Table 1. Baseline characteristics of patients.

Without ESCC (n = 1.739) With ESCC (n = 149) Missed values P
Age (years) 59.1 ± 10.0 57.3 ± 9.4 0 0.035 1
Sex 1.739 (100.0) 149 (100.0) 0 0.033

  • Male

 1.475 (84.8) 136 (91.3)

  • Female

 264 (15.2) 13 (8.7)
Location of HNSCC 1.739 (100.0) 149 (100.0) 0 0.001

  • Oral cavity

 408 (23.5) 48 (32.4)

  • Oropharynx

 523 (30.1) 57 (38.5)

  • Nasopharynx

 42 (2.4) 0 (0.0)

  • Hypopharynx

 125 (7.2) 13 (8.8)

  • Larynx

 620 (35.6) 30 (20.1)

  • Occult primary tumor

 21 (1.2) 1 (0.7)
Stage of HNSCC 1.610 (100.0) 123 (100.0) 129/26  < 0.001

  • Stage 0

 14 (0.9) 3 (2.4)

  • Stage I

 172 (10.7) 9 (7.3)

  • Stage II

 138 (8.6) 10 (8.1)

  • Stage III

 270 (16.8) 19 (15.4)

  • Stage Iva

 774 (48.1) 56 (45.5)

  • Stage IVb

 237 (14.7) 21 (17.1)

  • Stage IVc

 5 (0.3) 5 (4.1)
Treatment of HNSCC 1.731 (100.0) 147 (100.0) 8/2  < 0.001

  • Radiotherapy and/or chemotherapy

 749 (43.3) 95 (64.6)

  • Surgery alone

 286 (16.5) 10 (6.8)

  • Surgery + chemotherapy

 9 (0.5) 1 (0.7)

  • Surgery + radiotherapy

 257 (14.8) 9 (6.1)

  • Surgery + chemoradiotherapy

 395 (22.8) 27 (18.4)

  • None

 35 (2.0) 5 (3.4)
ECOG scale 1.646 (100.0) 139 (100.0) 83/10  < 0.001

  • 0

 548 (33.3) 22 (15.8)

  • 1

 851 (51.7) 89 (64.0)

  • 2

 161 (9.8) 23 (16.5)

  • 3

 72 (4.4) 5 (3.6)

  • 4

 14 (0.9) 0 (0.0)
Dysplasia 1.739 (100.0) 149 (100.0) 0  < 0.001 2

  • No

 1707 (98.2) 130 (87.2)

  • Yes

 32 (1.8) 19 (12.8)
Other second primary tumor (except esophagus) 1.737 (100.0) 149 (100.0) 2/0 0.906

  • No

 1.545 (88.9) 133 (89.3)

  • Yes

 192 (11.1) 16 (10.7)

HNSCC, head and neck squamous cell carcinoma; ECOG, Eastern Cooperative Oncology Group.

1

Student’s t -test.

2

Chi-square or Fisher test.